A Golden Hour and Golden Opportunity for β-Cell Preservation
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Natural history studies, intervention trials, and transplantation studies consistently show that higher C-peptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced long-term complications.
“natural history studies, intervention trials, and transplantation studies consistently show that higher Cpeptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced longterm complications.[55][56][57]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [56]
In the section discussing DCCT/EDIC and the intervention-trial evidence (page not provided), the paper links preserved C-peptide with improved glycaemic control and describes indirect evidence for fewer hypoglycaemic episodes and complications. It says hypoglycaemia was inconsistently measured across trials, so the claim overstates how consistently all three study types show all three outcomes. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · see citing works
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771 · see citing works
Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216 · see citing works
Gregory, G. A., Robinson, T. I. G., Linklater, S. E., Wang, F., Colagiuri, S., de Beaufort, C., Donaghue, K. C., Harding, J. L., Wander, P. L., Zhang, X., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00218-2 · Cited by 1,149 · see citing works
Self-citationEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941 · see citing works
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 590 · see citing works
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491 · see citing works
The Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting
Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 201 · see citing works
Wagner, J. A., Williams, S., & Webster, C. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100017 · Cited by 201 · see citing works
Endpoints for clinical trials in ophthalmology
Schmetterer, L. F., Scholl, H. P. N., Garhöfer, G., Janeschitz‐Kriegl, L., Corvi, F., Sadda, S. R., & Medeiros, F. A. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101160 · Cited by 90 · see citing works
Gubitosi-Klug, R. A., Braffett, B. H., Hitt, S., Arends, V., Uschner, D., Jones, K., Diminick, L., Karger, A. B., Paterson, A. D., Roshandel, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143011 · Cited by 86 · see citing works
Teplizumab approval for type 1 diabetes in the USA
Evans‐Molina, C., & Oram, R. A. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00390-4 · Cited by 72 · see citing works
Self-citationPrevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 68 · see citing works
Taylor, P. N., Collins, K. S., Lam, A. P., Karpen, S. R., Greeno, B., Walker, F., Lozano, A., Atabakhsh, E., Ahmed, S. T., Marinac, M., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00267-x · Cited by 67 · see citing works
The Diabetes Control and Complications Trial: the gift that keeps giving
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.179 · Cited by 59 · see citing works
Latres, E., Greenbaum, C. J., Oyaski, M. L., Dayan, C. M., Colhoun, H. M., Lachin, J. M., Skyler, J. S., Rickels, M. R., Ahmed, S. T., Dutta, S., et al. (2024) · Diabetes · doi:10.2337/dbi23-0012 · Cited by 35 · see citing works
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
Ylescupidez, A., Bahnson, H. T., O’Rourke, C., Lord, S. M., Speake, C., & Greenbaum, C. J. (2023) · Nature Communications · doi:10.1038/s41467-023-42581-z · Cited by 27 · see citing works
A quantitative measure of treatment response in recent‐onset type 1 diabetes
Bundy, B. N., Krischer, J. P., & for the Type 1 Diabetes TrialNet Study Group (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.143 · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The future of type 1 diabetes therapy
Ziegler, A.-G., Cengiz, E., & Kay, T. W. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01438-2 · Cited by 42 · see citing works
Evans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06462-y · Cited by 24 · see citing works
Self-citationMittal, R., Weiss, M. B., Rendon, A., Shafazand, S., Lemos, J. R. N., & Hirani, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093935 · Cited by 21 · see citing works
Emerging Immunotherapies for Disease Modification of Type 1 Diabetes
Foster, T. P., Bruggeman, B., & Haller, M. J. (2025) · Drugs · doi:10.1007/s40265-025-02150-8 · Cited by 19 · see citing works
Evans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetes Care · doi:10.2337/dci25-0013 · Cited by 16 · see citing works
Self-citationBeese, S. E., Price, M. J., Tomlinson, C. L., Sharma, P., Harris, I. M., Adriano, A., Quinn, L. M., Gada, R., Horgan, T. J., Maggs, F., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04201-z · Cited by 17 · see citing works
Call for Standardization of C-Peptide Measurement
Schleicher, E. D., Kabytaev, K., Nauck, M., Müller‐Wieland, D., Peter, A., Little, R. R., & Heinemann, L. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251362848 · Cited by 10 · see citing works
Evans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetes · doi:10.2337/dbi25-0011 · Cited by 7 · see citing works
Self-citationSystem Failure in Type 1 Diabetes: What Stakeholders Need to Know to Expedite Therapeutic Options
Dayan, C. M., Mathieu, C., Lowenstein, D., & Soler, L. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0024
He, X. Y., Zhang, H., Zhang, Y., Wu, J., Wang, T., Liu, Y., Jin, K., Tang, W., Ye, Q., & Wang, Q. (2026) · Medical Oncology · doi:10.1007/s12032-026-03448-7
- Authors
- Evans-Molina, C., & Oram, R. A.
- Affiliations
- 1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN
- National Health Service (GB)
- Corresponding author
- Oram, Richard A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2024-05-20
- Volume
- 73
- Issue
- 6
- Pages
- 834-836
- ISSN
- 0012-1797 (ISSN-L)
- PMC
- PMC11109773
- OpenAlex
- W4398143848
- Cited by
- 10
- References
- 18
- Citations by year
- 2026: 1 · 2025: 9
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Funders
- Larry M and Leona B Helmsley Charitable Trust
- Randox Ltd
- U.S. Department of Veterans Affairs Merit Award (I01BX001733)
- Ball Brothers Foundation
- Sigma Beta Sorority
- National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121843-01, R01DK093954, R01DK127236, R01DK127308, U01DK127382-01, U01DK127786, UC4DK104166)
- George and Frances Ball Foundation
- Diabetes UK Harry Keen Fellowship (16/0005529)
- JDRF (2-SRA-2002-1259-S-B, 2-SRA-2022-1258-M-B, 2-SRA-2022-1261-S-B, 3-SRA-2019-827-S-B, 3-SRA-2022-1241-S-B)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- beta-cell preservation, beta-cell function, pancreatic islets
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Humans, Preservation, Biological, United States Food and Drug Administration, Islets of Langerhans Transplantation, Drug Approval, Insulin-Secreting Cells, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
